BioCorRx Inc (BICX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:BioCorRx Inc (BICX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9443
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:45
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
BioCorRx Inc (BioCorRx), formerly Fresh Start Private Management Inc, is a healthcare solution provider. The company provides alcoholism and opioid addiction treatment program for use in rehabilitation and treatment centers. It distributes and licenses BioCorRx recovery program, a medication-assisted treatment (MAT) program that includes a counseling program coupled with its proprietary naltrexone implant. It also develops BICX101, an injectable naltrexone product; and BICX102, an implantable naltrexone implant for the treatment of alcohol and opioid addiction. The company distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. BioCorRx is headquartered in Anaheim, California, the US.

BioCorRx Inc (BICX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
BioCorRx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
BioCorRx Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
BioCorRx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
BioCorRx Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
BioCorRx Inc, Medical Devices Deals, 2012 to YTD 2018 10
BioCorRx Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
BioCorRx Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Biocorrx Acquires Portfolio from Therakine Biodelivery 12
BioCorRx Acquires Intellectual Property and Contractual Rights of Well Advised 13
Private Equity 14
Alpine Creek Capital Partners to Invest USD1.66 Million in BioCorRx 14
Partnerships 15
BioCorRx Enters into Licensing Agreement with Therakine 15
BioCorRx to Enter into Agreement with VDM Biochemicals 16
Licensing Agreements 17
BioCorRx Enters into Licensing Agreement with Fresh Start Private Midwest 17
Equity Offering 18
BioCorRx Raises USD1.1 Million in Private Placement of Units 18
Debt Offering 19
BioCorRx Raises USD0.08 Million in Private Placement of Note 19
BioCorRx Raises USD0.08 Million in Private Placement of Note 20
BioCorRx Raises USD0.3 Million in Private Placement of Note 21
BioCorRx Inc – Key Competitors 22
BioCorRx Inc – Key Employees 23
BioCorRx Inc – Locations And Subsidiaries 24
Head Office 24
Recent Developments 25
Product News 25
07/25/2017: BioCorRx Announces EnLite Clinics to Implement the BioCorRx Recovery Program in Three Clinics in Ohio 25
07/06/2017: BioCorRx to Exhibit at ASAM Conference in Dallas, Texas 26
05/22/2018: BioCorRx Announces Grant Submission to the National Institutes of Health for BICX102 27
04/30/2018: BioCorRx Gains Additional Media Coverage from Fox Medical Correspondent Who Discusses the Advantages of the Naltrexone Implant 28
04/26/2018: BioCorRx CEO Brady Granier and Actor Jeremy Miller Appear on Varney & Co. on Fox Business to Discuss the Company’s Sustained Release Naltrexone Implant for Alcohol Use Disorder 29
04/05/2018: BioCorRx Partner, Virtual Reality Medical Center, Submits Small Business Innovation Grant Application to the National Institute of Health 30
01/05/2018: BioCorRx Retains Regulatory Drug Expert Priya Jambhekar and CMC Expert Bruce Firestone 31
01/02/2018: BioCorRx CEO, Brady Granier, Appears on Fox & Friends to Discuss the Opioid Epidemic 32
Product Approvals 33
Feb 12, 2018: BioCorRx Announces Results of Pre-IND meeting with FDA for Sustained Release Naltrexone Implant, BICX102 33
Dec 19, 2017: BioCorRx Submits Pre-IND Package to FDA for its Naltrexone Implant, BICX102 34
Sep 28, 2017: BioCorRx Announces Update on Commercialization Efforts for Naltrexone Implant 35
Jan 12, 2017: BioCorRx Retains Innovative Science Solutions to Guide FDA Regulatory Process for its Naltrexone Products 36
Other Significant Developments 37
Apr 06, 2018: BioCorRx Provides Business Update for the Full Year Ended 2017 37
Mar 15, 2018: BioCorRx Provides Update on New Weight Management Program 39
Nov 17, 2017: BioCorRx Provides Business Update for the Third Quarter of 2017 40
Sep 12, 2017: BioCorRx Announces Beta Launch of Mobile Application for Opioid and Alcohol Substance Use Disorder 41
Aug 15, 2017: BioCorRx Reports 12% Increase in Revenue and Provides Business Update for the Second Quarter of 2017 42
Jul 31, 2017: Serrano Kidney and Vascular Access Center to Implement the BioCorRx Recovery Program for the Hispanic Market in Los Angeles 44
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45

List of Tables
BioCorRx Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
BioCorRx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
BioCorRx Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
BioCorRx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
BioCorRx Inc, Deals By Therapy Area, 2012 to YTD 2018 9
BioCorRx Inc, Medical Devices Deals, 2012 to YTD 2018 10
BioCorRx Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Biocorrx Acquires Portfolio from Therakine Biodelivery 12
BioCorRx Acquires Intellectual Property and Contractual Rights of Well Advised 13
Alpine Creek Capital Partners to Invest USD1.66 Million in BioCorRx 14
BioCorRx Enters into Licensing Agreement with Therakine 15
BioCorRx to Enter into Agreement with VDM Biochemicals 16
BioCorRx Enters into Licensing Agreement with Fresh Start Private Midwest 17
BioCorRx Raises USD1.1 Million in Private Placement of Units 18
BioCorRx Raises USD0.08 Million in Private Placement of Note 19
BioCorRx Raises USD0.08 Million in Private Placement of Note 20
BioCorRx Raises USD0.3 Million in Private Placement of Note 21
BioCorRx Inc, Key Competitors 22
BioCorRx Inc, Key Employees 23

List of Figures
BioCorRx Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
BioCorRx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
BioCorRx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
BioCorRx Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
BioCorRx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
BioCorRx Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
BioCorRx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
BioCorRx Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
BioCorRx Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[BioCorRx Inc (BICX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Hachsharat Hayishuv Hotels Ltd.
    Hachsharat Hayishuv Hotels Ltd. - Strategy, SWOT and Corporate Finance Report Summary Hachsharat Hayishuv Hotels Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Presence Health:企業の戦略的SWOT分析
    Presence Health - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • China Resources Pharmaceutical Group Ltd (3320):製薬・医療:M&Aディール及び事業提携情報
    Summary China Resources Pharmaceutical Group Ltd (CR Pharma), a subsidiary of China Resources (Holdings) Co Ltd is a pharmaceutical company that offers nutritional supplements. The company offers research and development, manufacture, and distribution of whole drug products. Its products comprise ch …
  • iMDsoft Inc:企業の戦略的SWOT分析
    iMDsoft Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Canadian Energy Services & Technology Corp. (CEU):石油・ガス:M&Aディール及び事業提携情報
    Summary Canadian Energy Services & Technology Corp (CES) is a provider of chemical solutions. It provides technically advanced consumable chemical solutions for the North American oil and gas industry. The total solution provided by the company includes the drill-bit, at the point of completion and …
  • InterContinental Hotels Group Plc:企業の戦略・SWOT・財務情報
    InterContinental Hotels Group Plc - Strategy, SWOT and Corporate Finance Report Summary InterContinental Hotels Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • EDF Energy Holdings Ltd:発電所・企業SWOT分析
    EDF Energy Holdings Ltd - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key emplo …
  • Belfius Bank Sa:企業の戦略・SWOT・財務分析
    Belfius Bank Sa - Strategy, SWOT and Corporate Finance Report Summary Belfius Bank Sa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Gridsum Holding, Inc. (GSUM):企業の財務・戦略的SWOT分析
    Gridsum Holding, Inc. (GSUM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Mylan N.V.:企業のM&A・事業提携・投資動向
    Mylan N.V. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Mylan N.V. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • Recordati SpA (REC):製薬・医療:M&Aディール及び事業提携情報
    Summary Recordati SpA (Recordati), a subsidiary of Fimei SpA is a pharmaceutical company that researches, develops, manufactures and markets pharmaceuticals. The company offers pharmaceuticals for cardiovascular diseases, dermatology, central nervous system disorders, musculo-skeletal disorders and …
  • CytoSorbents Corp (CTSO)-製薬・医療分野:企業M&A・提携分析
    Summary CytoSorbents Corp (CytoSorbents), formerly MedaSorb Technologies Corp, is a critical care immunotherapy company that specializes in the development of blood purification products. Its flagship product, CytoSorb is an extracorporeal cytokine adsorber that is designed to control extreme system …
  • Steven Madden Ltd (SHOO):企業の財務・戦略的SWOT分析
    Steven Madden Ltd (SHOO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Martin Midstream Partners L.P.:企業の戦略・SWOT・財務情報
    Martin Midstream Partners L.P. - Strategy, SWOT and Corporate Finance Report Summary Martin Midstream Partners L.P. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Isetan Mitsukoshi Holdings Ltd.:戦略・SWOT・企業財務分析
    Isetan Mitsukoshi Holdings Ltd. - Strategy, SWOT and Corporate Finance Report Summary Isetan Mitsukoshi Holdings Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • TxCell SA (TXCL):企業の財務・戦略的SWOT分析
    Summary Txcell SA (Txcell) a subsidiary of Sangamo Therapeutics Inc, is a biotechnology company that develops personalized cellular immunotherapies using regulatory T cells (Treg) for the treatment of autoimmune and inflammatory diseases as well as transplantation-related inflammatory disorders. The …
  • Volkswind GmbH:電力:M&Aディール及び事業提携情報
    Summary Volkswind GmbH (Volkswind) a subsidiary of Axpo Holding AG, is an independent renewable power producer. It undertakes the planning, development, construction and operations of wind power plants. Volkswind builds wind farms with wind turbines from various suppliers including Seimens, Enercon, …
  • Ingosstrakh Joint-Stock Insurance Company Ltd.:企業の戦略・SWOT・財務分析
    Ingosstrakh Joint-Stock Insurance Company Ltd. - Strategy, SWOT and Corporate Finance Report Summary Ingosstrakh Joint-Stock Insurance Company Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, ope …
  • Mitsubishi Logistics Corporation (9301):企業の財務・戦略的SWOT分析
    Mitsubishi Logistics Corporation (9301) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • VidaCaixa, S.A.U. de Seguros y Reaseguros:企業の戦略・SWOT・財務情報
    VidaCaixa, S.A.U. de Seguros y Reaseguros - Strategy, SWOT and Corporate Finance Report Summary VidaCaixa, S.A.U. de Seguros y Reaseguros - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆